Nice | Empagliflozin in Type 2 Diabetes

5th June 2015 by Louise Hudman

Nice | Empagliflozin in Type 2 Diabetes

This is a new guideline from Nice. Empagliflozin is a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor, which blocks glucose reabsorption in the kidneys and so causes increased urinary excretion. For other SGLT-2 inhibitors have been approved by NICE, see my post about Dapagliflozin.

Empagliflozin use in Type 2 Diabetes

  • as a 2nd drug in combination with metformin if they
    • can not take sulphonylureas.
    • are at significant risk of hypoglycaemia or its consequences.
  • as a 3rd drug with metformin and either a sulphonylurea or a thiazolinedione.
  • in combination with insulin with or without other drugs.

Read for free

Sign up to access everything.

Free trial


Already a member? Login to view this content.


"I feel strongly that sessional GPs need an organisation solely focussed on representing their interests."

Dr Tim Cantor

See the full list of features within our NASGP membership plans